The RITUXAN for RA EXPERIENCE Program

 

through Genentech
Rheumatology
Access Solutions

$4,000 per
12-month period
toward the cost of
Rituxan for eligible patients

Learn More

Indication

Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

RITUXAN administration can result in serious, including fatal, adverse reactions. These include: infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML).

Warnings and Precautions

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

  • hepatitis B reactivation
  • other infections including bacterial, fungal, new or reactivated viral infections
  • cardiovascular events

Patients should be closely observed for signs of infection if biologic agents and /or DMARDs other than methotrexate are used concomitantly

Common adverse reactions include infusion reactions and infections

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

Print Page
 

Use of another biologic therapy after Rituxan was not associated with an increased risk of serious infections

Rate of serious infections  
  • 83% of patients had peripheral B-cell levels below the lower limit of normal at time of subsequent treatment11
  • Median time to subsequent treatment post Rituxan: 8.5 months (range 0.1 months to 52 months)11

Adapted from Genovese 2010.11

 

This safety follow-up analysis included patients who received a range of other treatments

Safety follow-up analysis

b
Percentages do not total 100% because some patients received more than 1 type of biologic.
Reference
11.
Genovese MC, Breedveld F, Emery P, et al. Rate of serious infections in RA patients who subsequently receive other biologic therapies after discontinuing rituximab treatment. Presented at European League Against Rheumatism Conference; June 16-19, 2010; Rome, Italy.